In a phase 2a trial of 29 patients with non-transfusion-dependent β-thalassaemia intermedia, sapablursen (30–160 mg every 4 weeks for up to 2 years) was generally well tolerated but did not raise haemoglobin or reduce liver iron content, its primary and secondary end points.
RCTn = 29
Taher et al. A phase 2a randomized study to evaluate sapablursen in patients with non-transfusion-dependent β-thalassemia intermedia